Do Pennsylvania Physicians Need to Worry About Dispensing Compounded GLP-1s?
The explosive growth in demand for GLP-1 medications for weight loss and diabetes management has created enormous opportunities for physicians, medspas, and weight-loss clinics. Medications such as Ozempic®, Wegovy®, and Mounjaro® are gaining widespread interest across the country. Widespread shortages beginning in 2022 left many patients unable to obtain brand-name medications, leading providers to increasingly rely upon compounded GLP-1 products as an alternative. Many of those shortages have since expired, but physicians have continued to rely on compounded products. Pennsylvania physicians and clinics should understand the legal, regulatory, and professional risks associated with prescribing and dispensing compounded GLP-1s.
Patient Safety and Product Quality Risks
Compounded GLP-1 medications present unique patient safety concerns because they are not FDA-approved products and are not subject to the same manufacturing oversight as brand-name medications. Providers should be aware of the growing concerns involving counterfeit or adulterated GLP-1 products entering the marketplace, particularly as demand continues to rise.
Quality issues may also arise from improper compounding practices, inconsistent concentrations of active ingredients, or contamination during preparation. In addition, many GLP-1 medications require refrigeration and careful temperature control during shipping and storage. Improper handling may affect the medication’s potency or stability before it reaches the patient.
Dosing concerns are another significant issue. Inconsistencies in compounded formulations may increase the risk of side effects, result in ineffective treatment, or dosing errors. It is crucial that any prescribing or dispensing physician understand the dosing for any compounded product.
The FDA has made enforcement efforts against compounded GLP-1s a priority over the past few years, highlighting the risk to patient safety: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Informed Consent Concerns
Pennsylvania physicians should also consider the professional liability risks associated with compounded GLP-1s. In particular, providers may face allegations that patients were not adequately informed regarding the differences between compounded medications and FDA-approved alternatives.
Informed consent discussions should clearly explain that compounded GLP-1s are not FDA-approved products and may involve additional risks related to quality, consistency, or efficacy. Providers should also discuss the availability of brand-name alternatives when appropriate. Failure to properly document these conversations may expose a physician to risk if a patient later experiences an adverse outcome or alleges they were misled regarding the nature of the medication being provided.
State Board Enforcement
As the use of compounded GLP-1 products continues to proliferate, the Pennsylvania State Boards of Medicine and Pharmacy may increase scrutiny related to compounded medications.
Most recently, the Shapiro Administration signaled its interest in enforcement efforts by fining a Chester County Pharmacy $1 million and placing its license on probation for producing and distributing approximately 30,000 doses of injectable weight-loss drugs in uninspected facilities. An investigation revealed that the pharmacy compounded and packaged GLP-1 medications without informing inspectors or obtaining proper approvals for its facilities.
The Pennsylvania State Boards of Medicine and Pharmacy may follow the lead of other states that are taking action against physician practices – for example, the Alabama Attorney General filed suit against a wellness clinic for injecting patients with unsafe, research-grade weight-loss drugs, falsely advertised as “pharmaceutical-grade” versions of brand-name GLP-1 medications.
Advertising and Trademark Risks
Marketing compounded GLP-1 medications may create additional legal exposure. Some clinics advertise compounded semaglutide or tirzepatide products using the names of FDA-approved medications such as Ozempic or Wegovy. Doing so may expose providers to claims involving deceptive advertising, consumer protection violations, or trademark infringement.
Notably, some of the largest manufacturers of GLP-1s have pursued trademark infringement actions against providers advertising compounded products as brand-name drugs. The proliferation of advertisements on social media has made it easy for the manufacturers to target providers inadvertently marketing compounded products as “Ozempic” or “Wegovy.”
The Connecticut Attorney General has issued warnings that advertising compounded GLP-1 products could violate Connecticut's Unfair Trade Practices Act to weight-loss clinics, med spas, and medical practices. It is possible that the Pennsylvania Attorney General could take similar actions against physician practices in the Commonwealth.
Providers should avoid marketing compounded medications in a manner that could lead patients to believe they are receiving the brand-name product itself. Advertising materials, websites, and social media content should accurately identify compounded medications as compounded products and avoid misleading claims regarding equivalence, safety, or FDA approval.
Compliance Considerations
As compounded GLP-1 medications continue to grow in popularity, Pennsylvania physicians and weight-loss clinics should take proactive steps to reduce their risks. Providers should carefully vet compounding pharmacies that supply their products, implement detailed informed consent procedures, establish clear policies governing advertising and marketing practices, and monitor enforcement actions at the state and federal levels. By focusing on patient safety, transparency, and regulatory compliance, clinics can better position themselves to navigate the evolving legal landscape surrounding compounded GLP-1 therapies.
If you have any questions about implementing appropriate compliance measures in your practice, please contact Evan Sampson, Counsel in the firm’s Health Care Practice Group, at 856.301.2561 or esampson@postschell.com.
Disclaimer: This post does not offer specific legal advice, nor does it create an attorney-client relationship. You should not reach any legal conclusions based on the information contained in this post without first seeking the advice of counsel.
